| __timestamp | Alnylam Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 612613000000 |
| Thursday, January 1, 2015 | 60610000 | 650773000000 |
| Friday, January 1, 2016 | 89354000 | 619061000000 |
| Sunday, January 1, 2017 | 199365000 | 628106000000 |
| Monday, January 1, 2018 | 382359000 | 717599000000 |
| Tuesday, January 1, 2019 | 479005000 | 964737000000 |
| Wednesday, January 1, 2020 | 588420000 | 875663000000 |
| Friday, January 1, 2021 | 620639000 | 886361000000 |
| Saturday, January 1, 2022 | 770658000 | 997309000000 |
| Sunday, January 1, 2023 | 795646000 | 1053819000000 |
| Monday, January 1, 2024 | 975526000 | 1053819000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, operational costs play a pivotal role in shaping company strategies. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Takeda Pharmaceutical Company Limited and Alnylam Pharmaceuticals, Inc., from 2014 to 2023.
Takeda, a leader in the field, consistently reported SG&A expenses exceeding $600 billion annually, peaking at over $1 trillion in 2023. This reflects a robust operational framework, essential for maintaining its global presence. In contrast, Alnylam, a smaller yet innovative player, saw its SG&A expenses grow from $45 million in 2014 to nearly $800 million in 2023, marking an impressive 1,700% increase. This surge underscores Alnylam's aggressive expansion and investment in research and development.
While Takeda's expenses remained relatively stable, Alnylam's rapid growth trajectory highlights its strategic focus on scaling operations and market penetration.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Who Generates More Revenue? Takeda Pharmaceutical Company Limited or Alnylam Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited and Incyte Corporation: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Takeda Pharmaceutical Company Limited or Xencor, Inc.: Who Manages SG&A Costs Better?
Takeda Pharmaceutical Company Limited and Evotec SE: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.